Cargando…

Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus

AIM: The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus therapy for subjects with gestational diabetes mellitus (GDM). METHODS: In a randomized, parallel-group, open-labelled tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pettitt, D. J., Ospina, P., Howard, C., Zisser, H., Jovanovic, L.
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2007
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2121124/ https://www.ncbi.nlm.nih.gov/pubmed/17888133 http://dx.doi.org/10.1111/j.1464-5491.2007.02247.x

Ejemplares similares

Insulin aspart in patients with gestational diabetes mellitus and pregestational diabetes mellitus
por: Deepaklal, M. C., et al.
Publicado: (2015)

Effects of insulin aspart and metformin on gestational diabetes mellitus and inflammatory markers
por: Wang, Yan, et al.
Publicado: (2023)

Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
por: Shah, Viral N., et al.
Publicado: (2021)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
por: Heller, Simon, et al.
Publicado: (2013)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

The OmniPod Insulin Management System: the latest innovation in insulin pump therapy
por: Zisser, Howard C.
Publicado: (2010)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience
por: Chawla, Manoj, et al.
Publicado: (2015)

Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2023)

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
por: Aravind, S. R., et al.
Publicado: (2022)

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog(®)) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
por: Blevins, Thomas C., et al.
Publicado: (2022)

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
por: Garg, Satish K., et al.
Publicado: (2020)

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
por: Buse, John B., et al.
Publicado: (2018)

Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A(1)chieve Study
por: Hajjaji, Issam, et al.
Publicado: (2014)

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
por: Grunberger, George, et al.
Publicado: (2020)

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
por: Leelarathna, Lalantha, et al.
Publicado: (2018)

Prediction of insulin treatment in women with gestational diabetes mellitus
por: Eleftheriades, Makarios, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Edina, Brenda C, et al.
Publicado: (2022)

SUN-LB117 Faster Acting Insulin Aspart in Patients With Gestational Diabetes Mellitus - an Early Experience From India
por: Bhattacharyya, Supratik
Publicado: (2020)

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
por: Lane, Wendy S., et al.
Publicado: (2020)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Metformin, Glyburide, and Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis
por: Guo, Lanlan, et al.
Publicado: (2019)

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
por: Hermansen, Kjeld, et al.
Publicado: (2015)

Efficacy and Safety of Intramuscular Insulin Lispro vs. Continuous Intravenous Regular Insulin for the Treatment of Dogs With Diabetic Ketoacidosis
por: Malerba, Eleonora, et al.
Publicado: (2020)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature
por: Kumar, Ajay
Publicado: (2016)

Insulin Aspart Combined with Exercise Therapy in Spleen Deficiency Type Gestational Diabetes Mellitus: The Effect on Disease Control and Pregnancy Outcomes
por: Shi, Yingkun, et al.
Publicado: (2022)

Insulin: Lack of efficacy: case report
Publicado: (2022)

Gestational diabetes mellitus: Non-insulin management
por: Magon, Navneet, et al.
Publicado: (2011)

Insulin secretion and insulin resistance in Korean women with gestational diabetes mellitus and impaired glucose tolerance
por: Yang, Sae Jeong, et al.
Publicado: (2013)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial
por: Yang, Wenying, et al.
Publicado: (2019)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
por: Demir, Tevfik, et al.
Publicado: (2021)

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
por: Farshchi, Amir, et al.
Publicado: (2016)

Efficacy and Safety of Oral Antidiabetic Drugs in Comparison to Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis
por: Poolsup, Nalinee, et al.
Publicado: (2014)

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial
por: Mathieu, Chantal, et al.
Publicado: (2018)

Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin
por: Matheu, Victor, et al.
Publicado: (2005)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9temb0tpjsgmq41om0bsjjolhq